Biosynth offers the full range of peptide products and services to support your innovations in drug discovery.
From custom peptide synthesis and library production, lead discovery and optimization, large scale peptide manufacture and GMP compliant NCEs, as well as our class-leading neoantigen peptide programs. Biosynth’s Peptide division (formerly vivitde and Pepscan) supports your peptide project through (pre-) clinical development, application and commercialization.
Biosynth offers a unique CLIPS™ phage display platform to discover highly constrained de novo peptides with enhanced affinity against your target of interest, selectivity and proteolytic stability. We employ some of the industry’s finest chemists to further optimize and design your lead peptides to make them fit for your purpose.
Talk to the Biosynth team or visit our website if you want to know how we can make your drug discovery project a success story!
About Drug Discovery Innovation Programme 2022
Drug Discovery Innovation Programme is an invitation-only and one of the best platforms to learn the latest insights and develop lasting business relationships.
This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on thec adoption of technology to finding the solutions.
With over 100+ attendees, learn how modernization in R&D processes is fundamentally changing what the drug discovery research will look like in the next two to five years.
So, join us in 2022 for an in-person experience and 2-days of top-level strategic content and the current scientific insights, networking, and discussions from leading global pharmaceutical R&D executives.
Companies in attendance for 2022 will include Servier Pharmaceuticals, Monte Rosa Therapeutics, University of Oxford, WPD Pharmaceuticals, AISA Therapeutics, Anima Biotech, PDC*line Pharma, Eli Lillly and Company, Symphogen, IRB Barcelona, Axonis Therapeutics, Genentech, Arakis Therapeutics, Johnson & Johnson, Amgen, Revitale Pharma, Progenra Inc, CERo Therapeutics, Merck and much more.